News & Updates

Show Multimedia Only

Is dairy a health food or a health risk?

26 Jan 2026 by

Consumption of dairy products does not appear to increase the risk of noncommunicable diseases or mortality, according to a scoping review of systematic reviews and meta-analyses.

Is dairy a health food or a health risk?

26 Jan 2026

Body weight predicts dose reduction, discontinuation in HCC patients taking lenvatinib

26 Jan 2026

Patients with hepatocellular carcinoma (HCC) weighing <55 kg who initiate a full dose of lenvatinib tend to lose weight or discontinue treatment, reports a study.

Body weight predicts dose reduction, discontinuation in HCC patients taking lenvatinib

26 Jan 2026

SGLT2 inhibitors may keep ADT working longer in prostate cancer

23 Jan 2026 by

In prostate cancer patients receiving androgen deprivation therapy (ADT), concurrent use of SGLT2 inhibitors appears to delay hormone therapy failure.

SGLT2 inhibitors may keep ADT working longer in prostate cancer

23 Jan 2026

HPV genotyping enhances risk stratification of cervical samples

22 Jan 2026 by

A comprehensive human papillomavirus (HPV) genotyping in combination with cytology improves risk stratification of cervical samples and patient management, suggests a Singapore study.

HPV genotyping enhances risk stratification of cervical samples

22 Jan 2026

FLAURA2 regimen achieves median OS of nearly 4 years in EGFR-mutated advanced NSCLC

22 Jan 2026 by

First-line osimertinib plus chemotherapy demonstrated a median overall survival (mOS) of nearly 4 years in patients with EGFR-mutated (exon 19 deletion or L858R mutation) advanced non-small-cell lung cancer (NSCLC) in the final OS analysis of the FLAURA 2 trial.

FLAURA2 regimen achieves median OS of nearly 4 years in EGFR-mutated advanced NSCLC

22 Jan 2026

First phase III results show PFS benefit with pirtobrutinib vs BR in treatment-naïve CLL/SLL

22 Jan 2026 by

Single-agent pirtobrutinib significantly improved progression-free survival (PFS) vs bendamustine plus rituximab (BR) for patients with treatment-naïve chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL), according to the first results from the phase III BRUIN CLL-313 trial.

First phase III results show PFS benefit with pirtobrutinib vs BR in treatment-naïve CLL/SLL

22 Jan 2026

SGLT2i may delay hormone therapy failure in prostate cancer

22 Jan 2026 by

Intention-to-treat (ITT) SGLT2 inhibitor (SGLTi) use was associated with reduced risk of androgen deprivation therapy (ADT) and androgen receptor pathway inhibitor (APRI) failure, according to findings of a population-based study in Hong Kong.

SGLT2i may delay hormone therapy failure in prostate cancer

22 Jan 2026

$Liposomal irinotecan plus nimotuzumab takes on immunotherapy-refractory NPC$

Liposomal irinotecan plus nimotuzumab takes on immunotherapy-refractory NPC

21 Jan 2026 by

In patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) refractory to immune checkpoint inhibitor (ICI) therapy, the combination of liposomal irinotecan plus nimotuzumab yields meaningful clinical activity while having favourable tolerability, as shown in a phase II study.

Liposomal irinotecan plus nimotuzumab takes on immunotherapy-refractory NPC

21 Jan 2026

Savolitinib + osimertinib a potential option for Chinese patients with EGFR-mutated, MET-amplified NSCLC

21 Jan 2026 by

Chinese patients with locally advanced or metastatic, EGFR-mutated, MET-amplified non-small-cell lung cancer (NSCLC) whose disease progressed on first-line (1L) EGFR tyrosine kinase inhibitor (TKI) therapy obtain progression-free survival (PFS) benefit from the all-oral combination of savolitinib plus osimertinib vs platinum-based doublet chemotherapy, interim results of the phase III SACHI trial have shown.

Savolitinib + osimertinib a potential option for Chinese patients with EGFR-mutated, MET-amplified NSCLC

21 Jan 2026

Low-dose olanzapine as good as megestrol acetate for cancer anorexia–cachexia syndrome

20 Jan 2026 by

For vulnerable cancer patients undergoing chemotherapy, treatment with low-dose olanzapine works just as well as megestrol acetate in terms of promoting appetite and weight gain, as shown in a study.

Low-dose olanzapine as good as megestrol acetate for cancer anorexia–cachexia syndrome

20 Jan 2026

News & Updates

Showing Oncology articles

Showing

Specialty:

Is dairy a health food or a health risk?

Is dairy a health food or a health risk?

Body weight predicts dose reduction, discontinuation in HCC patients taking lenvatinib

Body weight predicts dose reduction, discontinuation in HCC patients taking lenvatinib

SGLT2 inhibitors may keep ADT working longer in prostate cancer

SGLT2 inhibitors may keep ADT working longer in prostate cancer

HPV genotyping enhances risk stratification of cervical samples

HPV genotyping enhances risk stratification of cervical samples

FLAURA2 regimen achieves median OS of nearly 4 years in EGFR-mutated advanced NSCLC

FLAURA2 regimen achieves median OS of nearly 4 years in EGFR-mutated advanced NSCLC

First phase III results show PFS benefit with pirtobrutinib vs BR in treatment-naïve CLL/SLL

First phase III results show PFS benefit with pirtobrutinib vs BR in treatment-naïve CLL/SLL

SGLT2i may delay hormone therapy failure in prostate cancer

SGLT2i may delay hormone therapy failure in prostate cancer

Liposomal irinotecan plus nimotuzumab takes on immunotherapy-refractory NPC

Liposomal irinotecan plus nimotuzumab takes on immunotherapy-refractory NPC

Savolitinib + osimertinib a potential option for Chinese patients with EGFR-mutated, MET-amplified NSCLC

Savolitinib + osimertinib a potential option for Chinese patients with EGFR-mutated, MET-amplified NSCLC

Low-dose olanzapine as good as megestrol acetate for cancer anorexia–cachexia syndrome

Low-dose olanzapine as good as megestrol acetate for cancer anorexia–cachexia syndrome